Haisco Pharmaceutical Group Co Ltd
SZSE:002653

Watchlist Manager
Haisco Pharmaceutical Group Co Ltd Logo
Haisco Pharmaceutical Group Co Ltd
SZSE:002653
Watchlist
Price: 33.07 CNY -2.19%
Market Cap: 37B CNY
Have any thoughts about
Haisco Pharmaceutical Group Co Ltd?
Write Note

Haisco Pharmaceutical Group Co Ltd
Other Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Haisco Pharmaceutical Group Co Ltd
Other Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Haisco Pharmaceutical Group Co Ltd
SZSE:002653
Other Current Liabilities
ÂĄ167.3m
CAGR 3-Years
-13%
CAGR 5-Years
-18%
CAGR 10-Years
0%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Other Current Liabilities
ÂĄ530.5m
CAGR 3-Years
-8%
CAGR 5-Years
-31%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Other Current Liabilities
ÂĄ299.9m
CAGR 3-Years
-28%
CAGR 5-Years
-13%
CAGR 10-Years
10%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Other Current Liabilities
ÂĄ3B
CAGR 3-Years
13%
CAGR 5-Years
20%
CAGR 10-Years
22%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Other Current Liabilities
ÂĄ3.6B
CAGR 3-Years
-3%
CAGR 5-Years
2%
CAGR 10-Years
15%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Other Current Liabilities
ÂĄ101.9m
CAGR 3-Years
5%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Haisco Pharmaceutical Group Co Ltd
Glance View

Market Cap
36.8B CNY
Industry
Pharmaceuticals

Haisco Pharmaceutical Group Co., Ltd. is an embodiment of relentless ambition and strategic foresight in China's burgeoning pharmaceutical landscape. Founded in 2000, the company quickly carved a niche for itself by focusing on the research, development, production, and sale of a diverse array of pharmaceutical products. Haisco's journey is rooted in an ethos of innovation and quality, as it sought to establish itself as a leader in the creation of anesthetics and antipyretic analgesics, among other critical therapeutic products. The company's prowess in research and development is clearly evident in its extensive pipeline and its state-of-the-art manufacturing facilities, which meet international standards. These capabilities allow Haisco to capture significant market share domestically and extend its reach into international markets. Where Haisco truly shines is in its operational model and financial acumen, driving its revenue streams through both business-to-business (B2B) and business-to-consumer (B2C) channels. On the B2B side, Haisco partners with hospitals, clinics, and other healthcare institutions to supply essential medications, ensuring a steady stream of revenue from bulk orders. Meanwhile, its direct-to-consumer sales strategy leverages in-depth market research to target retail pharmacies and end customers with a razor-sharp focus on effectiveness and affordability. By maintaining a dual-channel approach that capitalizes on economies of scale and robust distribution networks, Haisco not only amplifies its market penetration but also fortifies its financial performance. The company's strategic investments in technology and its commitment to stringent quality controls underpin its success, fostering trust and loyalty among consumers and partners alike.

Intrinsic Value
22.01 CNY
Overvaluation 33%
Intrinsic Value
Price

See Also

What is Haisco Pharmaceutical Group Co Ltd's Other Current Liabilities?
Other Current Liabilities
167.3m CNY

Based on the financial report for Sep 30, 2024, Haisco Pharmaceutical Group Co Ltd's Other Current Liabilities amounts to 167.3m CNY.

What is Haisco Pharmaceutical Group Co Ltd's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
0%

Over the last year, the Other Current Liabilities growth was -27%. The average annual Other Current Liabilities growth rates for Haisco Pharmaceutical Group Co Ltd have been -13% over the past three years , -18% over the past five years .

Back to Top